Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

Brian Pacheco New York The writer is the managing director of communications for the Drug Policy Alliance. To the Editor: Nicholas Kristof’s column starts with a faulty and harmful premise ...

When irbesartan therapy is discontinued, the dosage does not need to be tapered, regardless of the daily dose administered, because abrupt withdrawal of the drug is not associated with an increase ...

United States President Donald Trump has said that he will impose tariffs on automobile, semiconductor and pharmaceutical imports of around 25 percent and the announcement is set to come as soon ...

India, for example, is America’s top source of generic drugs, yet 70 percent of the active pharmaceutical ingredients in those drugs originate in China. As a result, the United States is ...

“And when we prioritize money at all costs, what we get is generic material that appeals to the most amount of people and we’re told that’s the best. It’s a dance we all do togethe ...

The drug had a 0.3mL favourable difference on the estimated glomerular filtration rate (eGFR) total slope and a 0.9mL annual favourable difference on the eGFR chronic slope compared with the control, ...

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has completed its Type C meeting with the U.S. Food and Drug Administration (FDA ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.